Translate this page into:
Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India
*Corresponding author: Dr. Aditya Kanoi. aditya.kanoi@gmail.com
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Introduction: Breast cancer is the leading oncogenic threat in South-East Asian women showing an inexplicable biological aggressiveness. High expression of cyclin D1, a key molecule in breast cancer pathogenesis, has been shown by previous studies in the Western world to be associated with favorable tumoral characteristics. Apart from determining the correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India, questions that we aimed to answer through this study included: Is there a significant regional difference in expression patterns of this protein? And if yes, can it possibly account for the epidemiological differences in breast cancer occurrence and biological behavior? Finally, is testing for overexpression of this protein in regions with limited resources beneficial? Materials and Methods: The present study was carried out on 110 previously untreated, female patients with primary breast carcinoma. Cyclin D1 expression was determined by immunohistochemistry using specific anti-cyclin D1 monoclonal antibodies. Results: Overexpression of cyclin Dl was found in 78 of 110 cases (70.9%). High expression of cyclin D1 showed a significant negative correlation with tumor size (P = 0.023) and tumor grade (P = 0.045). Estrogen receptor and progesterone receptor positive cases showed a significantly positive correlation with cyclin D1 overexpression (P = 0.026 and 0.046, respectively). Interestingly, cyclin D1 positivity showed a strong correlation with the type of surgical procedure performed (P = 0.002). Conclusion: Cyclin D1 overexpression in breast cancer is associated with less aggressive tumoral characteristics. Furthermore, its potential epidemiological role and utility as a prognostic marker have been discussed.
Keywords
References
- Boyle P. The globalisation of cancer. Lancet 2006;368:629-30.
- Breast cancer in developing countries. Lancet 2009;374:1567.
- Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
- Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-18.
- Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-87.
- Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 2005;103:2252-60.
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. C. W. Elston and I. O. Ellis. Histopathology 1991;19:403-10.
- Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.
- Mathew A, Pandey M, Rajan B. Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis? World J Surg Oncol 2004;2:2.
- Ghumare SS, Cunningham JE. Breast cancer trends in Indian residents and emigrants portend an emerging epidemic for India. Asian Pac J Cancer Prev 2007;8:507-12.
- Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009;18:1807-14.
- Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer 2002;99:747-50.
- Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999;5:2069-76.
- Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-34.
- Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
- Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
- Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
- Pelosio P, Barbareschi M, Bonoldi E, Marchetti A, Verderio P, Caffo O, et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 1996;7:695-703.
- van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997;150:705-11.